

OCT 16 2003

K032257

## **Section 7 510(k) Summary**

**Submitter:** Animas Corporation, 590 E. Lancaster Avenue, Frazer, PA 19355

**Contact:** Michael J. Andrews, Ph.D., Director, Regulatory Affairs,  
Telephone: (610)-644 8990, extension 1257, Fax: (610)-644-8717,  
Email: [michaeland@animascorp.com](mailto:michaeland@animascorp.com)

**Name of Device:** Animas Model IR 1200 Insulin Infusion Pump

**Predicate Device:** Animas IR 1000 Series Insulin Infusion Pump

**Description of the New Device:** The Animas Model IR 1200 Insulin Infusion Pump is an external syringe pump and delivery system that provides subcutaneous delivery of insulin for patients with diabetes mellitus who would benefit from a continuous insulin infusion process. The Model IR 1200 is used with an infusion set, e.g., the Animas ezSet™. The pump incorporates serial communications via an infrared (IR) interface. The user may download records from the pump for Daily Totals, Alarm History, Bolus History, as well as Basal Rate programs and Pump Settings. The pump is intended for multiple years of use and the insulin syringe is a sterile, single use disposable manufactured for Animas.

The system will deliver a prescribed dosage of insulin as a single programmable bolus or at multiple programmable basal rates. The system will also provide set up information, dosage history, alarms, error and warning messages, device status, and self test capabilities.

**Intended Use of the New Device:** The intended use of the Animas Model IR 1200 Insulin Infusion Pump is the same as that of the Series IR 1000 Insulin Infusion Pump, namely to provide subcutaneous delivery of insulin at programmable basal and bolus rates for the management of diabetes mellitus in insulin dependent patients.

This device is intended for home use and is a prescription device.

**Comparision of the Technological Features of the New Device and the Predicate Device:** The new device and the predicate device are nearly identical in terms of design, materials, and construction. The only differences are certain additional features found on the IR 1200 that make the IR 1200 more convenient for the user.

The differences between the new device and the predicate device do not affect the safety or effectiveness of the device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

OCT 16 2003

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. Richard R. Michelin  
Vice President Quality Assurance  
Animas Corporation  
590 E. Lancaster Avenue  
Frazer, Pennsylvania 19355

Re: K032257

Trade/Device Name: Animas Model IR 1200 Insulin Infusion Pump  
Regulation Number: 880.5725  
Regulation Name: Infusion Pump  
Regulatory Class: II  
Product Code: LZG  
Dated: July 21, 2003  
Received: July 22, 2003

Dear Ms. Andrews:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4618. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Susan R. Lin" with a stylized flourish at the end.

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## Section 9 Indications for Use Statement

510(k) Number: K032257

Device Name: Animas Model IR 1200 Insulin Infusion Pump

Indications for Use: The Animas Model Model IR 1200 Insulin Infusion Pump is intended to provide subcutaneous delivery of insulin at programmable basal and bolus rates for the daily management of diabetes mellitus in insulin dependent patients.

This device is intended for home use and is a prescription device.



(Division Sign-Off)  
Division of Anesthesiology, General Hospital  
Infection Control, Dental Devices

510(k) Number: K032257

---

Concurrence of CDRH, Office of Device Evaluation (ODE)